Literature DB >> 24636013

Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.

Jeffrey Fudin1, Timothy J Atkinson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24636013     DOI: 10.1111/pme.12417

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


× No keyword cloud information.
  2 in total

1.  OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form.

Authors:  Jeffrey Fudin; Mena Raouf; Erica L Wegrzyn
Journal:  J Pain Res       Date:  2016-09-07       Impact factor: 3.133

2.  Designing and conducting proof-of-concept chronic pain analgesic clinical trials.

Authors:  Claudia M Campbell; Ian Gilron; Tina Doshi; Srinivasa Raja
Journal:  Pain Rep       Date:  2019-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.